NCT03468972.

Trial name or title	Effect of immunosuppression in IgA nephropathy
Methods	Parallel RCT
Participants	Setting: multicentre (19 hospitals) Country: Korea Patients with biopsy‐proven IgAN within 5 years; persistent proteinuria who have preserved eGFR of ≥ 30 mL/min/1.73 m2; proteinuria < 1.0 g/g creatinine; 19 to 75 years, baseline eGFR ≥ 30 mL/min/1.73 m2 assessed by CKD‐EPI equation Number: estimated 87 subjects (a total of 174) would be required for each group Mean age ± SD (years): not yet available Sex (M/F): not yet available Exclusion criteria: nephrotic syndrome, atypical IgAN; crescents ≥ 25%; overt pulmonary tuberculosis; malignancy within 5 years of enrolment; pregnancy or breast feeding; active hepatitis, chronic hepatitis, liver cirrhosis, HIV; kidney transplant; current use of immunosuppressive treatment or prior use of immunosuppressive drugs within 1 year of enrolment; uncontrolled hypertension (> 160/100 mmHg); aged < 19 years; secondary IgAN such as lupus nephritis, chronic liver disease, or HSP; involvement of other clinical trials within 3 months of enrolment
Interventions	Treatment group 1 Corticosteroid Treatment group 2 Supportive care: including the use of RAS blockers, BP control with a target of < 130/80 mmHg, and protein restriction diet
Outcomes	Development of a ≥ 30% decline in eGFR Onset of ESKD Changes in urinary protein excretion and haematuria
Starting date	Estimated March 2019
Contact information	Seung Hyeok Han 82‐2‐2228‐1984 hansh@yuks.ac
Notes	Estimated study completion date: May 2023 No study results available